 |
|
|
| |
Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naïve participants from phase 3 clinical trials
|
| |
| |
Ernest Asante-Appiah, Merck & Co., Inc
IAC 2020 Virtual July 6-10 SF
Reported by Jules Levin
|
| |
|
|
|
|
|
